Seeing Is Believing
Currently out of the existing stock ratings of Matthew Barcus, 27 are a BUY (90%), 3 are a HOLD (10%).
Analyst Matthew Barcus, carries an average stock price target met ratio of 45% that have a potential upside of 74.34% achieved within 271 days. Previously, Matthew Barcus worked at CHARDAN CAPITAL.
Matthew Barcus’s has documented 55 price targets and ratings displayed on 10 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on QURE, Uniqure NV at 22-Jun-2023.
Analyst best performing recommendations are on IMNM (IMMUNOME ).
The best stock recommendation documented was for VINC (VINCERX PHARMA) at 3/30/2022. The price target of $30 was fulfilled within 77 days with a profit of $49 (62.03%) receiving and performance score of 8.06.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$33
$21.41 (184.73%)
$33
6 months 19 days ago
(20-Mar-2025)
2/6 (33.33%)
$24.34 (281.06%)
14
Buy
$21
$9.41 (81.19%)
$23
10 months 25 days ago
(14-Nov-2024)
0/3 (0%)
$9.86 (88.51%)
Buy
$9
$-3.38 (-27.30%)
$16
3 years 4 months 26 days ago
(13-May-2022)
2/2 (100%)
$6.76 (301.79%)
543
Buy
$33
$20.62 (166.56%)
$35
3 years 8 months 28 days ago
(11-Jan-2022)
0/2 (0%)
$21.36 (183.51%)
Buy
$21
$8.62 (69.63%)
$18
4 years 1 months 19 days ago
(20-Aug-2021)
2/2 (100%)
$8.5 (68.00%)
62
What Year was the first public recommendation made by Matthew Barcus?